List of Deliverables By Work Package
| No. | Deliverable Name | Lead | Type | Level |
| 1.1 | Project handbook and communications/documentation tools for file-sharing and discussion. | UCAM | R | CO |
| 1.2 | List of initial Advisory Board members on website | UCAM | R | PU |
| 1.3 | Midterm Report | UCAM | R | PU |
| 1.4 | Inaugural Advisory Board meeting [cancelled] | UCAM | Other | PU |
| 1.5 | EDPTC progress reports and financial reports | UCAM | R | CI |
| 2.0 | Preparation for import of materials to Ghana. Submission to FDA (and export from EU) | KCCR | OTHER | CO |
| 2.1 | Define end-user needs including the number of NAT systems and chips require for clinical testing | KCCR | R | CO |
| 2.2 | PATHPOD systems and chips delivered for clinical testing in Ghana | DTU | DEM | CO |
| 2.3 | Remote training course for use of PATHPOD system and chips | DTU | R | CO |
| 2.4 | Workflow for PATHPOD use in Ghana to detect COVID19 | DTU | DEM | CO |
| 3.1 | Engineered Boon2-BST and accompanying expression (inc autoinduction) and purification SOP | UCAM | DEM | PU |
| 3.2 | Engineered Boon2-RT and accompanying expression and purification SOP. | UCAM | DEM | PU |
| 3.3 | Application of Boon-enzymes in RT-LAMP protocol to detect SARS-Cov-2 | KNUST | DEM | PU |
| 3.4 | Demonstrate the BOON-RT and BST Production at 1-2 L | UCAM | DEM | CO |
| 3.5 | Engineered Boon2-scFV and accompanying expression and purification SOP. | UCAM | DEM | PU |
| 4.1 | Description of model for pooled samples at low, medium and high prevalences of COVID-19 | DTU | R | PU |
| 4.2 | Dataset for limit of detection and report on recommendations for clinical study design | KNUST | R | CO |
| 5.1 | Modified and characterised high-affinity scFv | UCAM | DEM | PU |
| 5.2 | Purified covid coat protein fragments | UCAM | DEM | PU |
| 5.3 | AfriMx protocol and SOP | UCAM | R | PU |
| 5.4 | Testing pre-screened clinical serum samples with AfriMx | KNUST | DEM | PU |
| 6.1 | Study protocol and supporting documents completed | KNUST | R | PU |
| 6.2 | Confirmation of study set up, recruitment and training of staff | KNUST | R | CO |
| 6.3 |
Institutional and regulatory approvals obtained (KNUST, UCAM) |
KNUST | R | PU |
| 6.4 | Provide data for mid term report | KNUST | R | CO |
| 6.5 | Comparative sample testing completed | KNUST | R | CO |
| 6.6 | Record of data collection and analysis | KNUST | R | CO |
| 6.7 | Publication of study report | KNUST | R | PU |
| 7.1 | Report and dataset on legal and regulatory landscape for PATHPOD and similar IVDs in Ghana | TATAA | R | PU |
| 7.2 | Commercialization plan for the Ghanaian market | TATAA | R | CO |
| 7.3 | Regulatory information compiled for IVD use in Ghana, in anticipation of future filing. | TATAA | R | CO |
| 8.1 | AfriDx Manufacturing course handbook and SOPs | UCAM | R | PU |
| 8.2 | AfriDx and AfriMx user course handbook and SOPs | NMIMR | R | PU |
| 8.3 | AfriDx-KIT DNA Collection, user course handbook and SOPs | UCAM | R | PU |
| 9.1 | Visual identity pack and website | UCAM | DEC | PU |
| 9.2 | Data Management Plan | UCAM | DEC | PU |
| 9.3 | Publication of Plan for Exploitation and Dissemination of Results | UCAM | R | PU |
| 9.4 | AfriDx Fact or Myth? Posts and explanatory short articles | DTU | DEC | PU |
| 9.5 | Video interviews with partners and stakeholders | UCAM | DEC | PU |
| 9.6 |
AfriDx policy briefs in electronic and printable format |
UCAM | DEC | PU |
